AdvisorShares Psychedelics ETF (PSIL) — ()
Key Metrics
News
5 Sector ETFs That Have Outperformed the S&P 500 in Q1
Published: by:
Sentiment: Positive ()
Here are a few ETFs that have outperformed the S&P 500 in the first quarter.
Read More
5 Best-Performing Sector ETFs Halfway Through Q1
Published: by:
Sentiment: Positive ()
At mid-way through the first quarter, Wall Street has been on a bull run, outplaying tariff trade war fears.
Read More
About AdvisorShares Psychedelics ETF PSIL
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.